menu
    • menu
    [{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PDC lung01","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"PDC lung01","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"PDC lung01","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Korea Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Korea Investment Partners"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korean Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"PDC lung01","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Korean Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Korean Investment Partners"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"BioWin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Dendritic Cell Vaccine","moa":"Cellular tumor antigen p53 (TP53)","graph1":"Oncology","graph2":"Preclinical","graph3":"PDC*line Pharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"PDC*line Pharma \/ BioWin","highestDevelopmentStatusID":"4","companyTruncated":"PDC*line Pharma \/ BioWin"}]

    Find Clinical Drug Pipeline Developments & Deals by PDC*line Pharma

    Menu

    PDC*line Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dendritic Cell Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : BioWin

                            Deal Size : $8.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            PDC*line Pharma Receives €8.1M for Personalized Therapeutic Vaccine Project from BioWin

                            Details : The net proceeds will be used to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology.

                            Product Name : PDC*Neo

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 17, 2024

                            Lead Product(s) : Dendritic Cell Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : BioWin

                            Deal Size : $8.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PDC lung01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PDC*line Pharma Completes Enrolment of Four Cohorts of Patients in PDC-LUNG-101 Phase I/II Clinical Trial

                            Details : PDC*lung01 is a vaccine administered via subcutaneous injection in combination with pemetrexed, being developed for non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            June 12, 2023

                            Lead Product(s) : PDC lung01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PDC lung01,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022

                            Details : Results showed that in a large proportion of subjects PDC*lung01, in monotherapy and combined with pembrolizumab, induces a significant expansion of effector memory CD8+ T-cells specific to the tumor peptides carried by PDC*lung01.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 12, 2022

                            Lead Product(s) : PDC lung01,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PDC lung01,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Korea Investment Partners

                            Deal Size : $20.3 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            PDC*Line Pharma Raises €17.5 Million ($20.3M) In Series B2 Financing Round

                            Details : Proceeds will primarily be used to fund company’s phase I/II trial with PDC*lung01, a vaccine candidate for lung cancer associated with or not with anti-PD-1 treatment in NSCLC.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 12, 2021

                            Lead Product(s) : PDC lung01,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Korea Investment Partners

                            Deal Size : $20.3 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PDC lung01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Korean Investment Partners

                            Deal Size : $22.2 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            PDC*line Pharma Raises €20 Million in Series B Financing Round

                            Details : Funding will support company’s phase I/II trial with PDC*lung01 candidate in lung cancer.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 22, 2020

                            Lead Product(s) : PDC lung01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Korean Investment Partners

                            Deal Size : $22.2 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed

                            PDC*line Pharma

                            France arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PDC*lung01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 31, 2019

                            Lead Product(s) : PDC*lung01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth